|
52 Companies |
|
55 Products |
|
55 Products |
|
44 Mechanisms of Action |
|
2 Trials |
|
148 News |
|
| 123» |
- || arsenic trioxide oral (SY-2101) / Syros
Trial completion, Trial completion date, Trial primary completion date, Metastases: A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders (clinicaltrials.gov) - Mar 25, 2019
P1, N=12, Completed, Sponsor: Orsenix LLC
Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Feb 2019 | Trial primary completion date: Aug 2019 --> Feb 2019
- | arsenic trioxide oral (SY-2101) / Syros
Trial completion date, Trial primary completion date, Metastases: A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders (clinicaltrials.gov) - Feb 21, 2019
P1, N=12, Active, not recruiting, Sponsor: Orsenix LLC
Active, not recruiting --> Completed | Trial completion date: Aug 2019 --> Feb 2019 | Trial primary completion date: Aug 2019 --> Feb 2019 Trial completion date: Mar 2021 --> Aug 2019 | Trial primary completion date: Mar 2020 --> Aug 2019
- | NN1213 / Novo Nordisk
Trial completion, Phase classification: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Jan 24, 2019
P1, N=90, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Mar 2021 --> Aug 2019 | Trial primary completion date: Mar 2020 --> Aug 2019 Active, not recruiting --> Completed | Phase classification: PN/A --> P1
- || arsenic trioxide oral (SY-2101) / Syros
Enrollment closed, Enrollment change, Metastases: A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders (clinicaltrials.gov) - Dec 24, 2018
P1, N=12, Active, not recruiting, Sponsor: Orsenix LLC
Active, not recruiting --> Completed | Phase classification: PN/A --> P1 Recruiting --> Active, not recruiting | N=20 --> 12
- | NN1213 / Novo Nordisk
Trial completion date, Trial termination: Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database (clinicaltrials.gov) - Dec 10, 2018
P=N/A, N=117, Terminated, Sponsor: Emory University
Recruiting --> Active, not recruiting | N=20 --> 12 Trial completion date: Nov 2019 --> Sep 2018 | Active, not recruiting --> Terminated; Previous principal investigators left institution
- | dilanubicel (DVX101) / Deverra Therapeutics
Phase classification, Enrollment change, Trial termination: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 26, 2018
P1, N=7, Terminated, Sponsor: Nohla Therapeutics, Inc.
Trial completion date: Nov 2019 --> Sep 2018 | Active, not recruiting --> Terminated; Previous principal investigators left institution Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Phase classification, Enrollment change, Trial termination: Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) - Aug 23, 2018
P1, N=7, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase classification: P=N/A --> P1 | N=15 --> 7 | Active, not recruiting --> Terminated Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply
- | Phase classification, Trial completion date, Trial primary completion date: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=90, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply Phase classification: P1 --> P=N/A | Trial completion date: Jun 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2018
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phase classification: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=0, Approved for marketing, Sponsor: Wake Forest University Health Sciences
Phase classification: P1 --> P=N/A | Trial completion date: Jun 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2018 Phase classification: P2 --> P=N/A
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Trial termination, Trial primary completion date: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 1, 2018
P2, N=12, Terminated, Sponsor: Wake Forest University Health Sciences
Phase classification: P2 --> P=N/A N=30 --> 12 | Suspended --> Terminated | Trial primary completion date: Aug 2020 --> Jul 2016
- cyclophosphamide / Generic mfg., clofarabine / Generic mfg.
Trial termination: POE07-01: Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (clinicaltrials.gov) - Feb 15, 2018
P1, N=35, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=30 --> 12 | Suspended --> Terminated | Trial primary completion date: Aug 2020 --> Jul 2016 Active, not recruiting --> Terminated; Lack of accrual
- ||| vadastuximab talirine (SGN-CD33A) / Pfizer
Trial completion: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Jan 5, 2018
P1, N=195, Completed, Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Terminated; Lack of accrual Active, not recruiting --> Completed
- arsenic trioxide oral (SY-2101) / Syros
Enrollment change, Metastases: A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders (clinicaltrials.gov) - Dec 8, 2017
P1, N=20, Recruiting, Sponsor: Orsenix LLC
Active, not recruiting --> Completed N=50 --> 20
- | lenalidomide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) - Sep 25, 2017
P1, N=17, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 20 Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012
- | Trial completion, Combination therapy: Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 20, 2017
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012 Active, not recruiting --> Completed
- || vadastuximab talirine (SGN-CD33A) / Pfizer
Trial primary completion date: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Aug 4, 2017
P1, N=195, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Mar 2016
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phase classification, Trial primary completion date: Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 1, 2017
P2, N=0, Withdrawn, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Jun 2017 --> Mar 2016 Phase classification: P=N/A --> P2 | Trial primary completion date: Mar 2018 --> Sep 2013
- | Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 24, 2017
P1, N=17, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P=N/A --> P2 | Trial primary completion date: Mar 2018 --> Sep 2013 Completed --> Active, not recruiting
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Phase classification: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - May 30, 2017
P2, N=30, Suspended, Sponsor: Wake Forest University Health Sciences
Completed --> Active, not recruiting Phase classification: P=N/A --> P2
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial suspension: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=30, Suspended, Sponsor: Wake Forest University Health Sciences
Phase classification: P=N/A --> P2 Recruiting --> Suspended
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 15, 2017
P=N/A, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Suspended Trial primary completion date: Jun 2017 --> Aug 2018
- arsenic trioxide oral (SY-2101) / Syros
New P1 trial, Metastases: A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders (clinicaltrials.gov) - Feb 9, 2017
P1, N=50, Recruiting, Sponsor: Orsenix LLC
- Enrollment closed, Trial primary completion date: Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database (clinicaltrials.gov) - Nov 25, 2016
P=N/A, N=117, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Jun 2017 --> Aug 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Nov 2016
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment closed: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 2, 2016
P=N/A, N=15, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2017 --> Nov 2016 Recruiting --> Active, not recruiting
- ||| New trial: French Registry of First-line Treatment of Acute Promyelocytic Leukemia (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=400, Recruiting, Sponsor: Groupe Francophone des Myelodysplasies
- Trial primary completion date: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - Oct 13, 2016
P0, N=90, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Apr 2017
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Aug 2016 --> Apr 2017 Trial primary completion date: Dec 2016 --> Jun 2017
- || vadastuximab talirine (SGN-CD33A) / Pfizer
Enrollment closed: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Jul 25, 2016
P1, N=195, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Dec 2016 --> Jun 2017 Enrolling by invitation --> Active, not recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission (clinicaltrials.gov) - Jun 26, 2016
P2, N=51, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg.
Trial termination: Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Jun 16, 2016
P2, N=88, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed Completed --> Terminated
- Trial completion, Trial primary completion date: Cell Samples From Patients With Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Completed --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Enrollment closed, Trial primary completion date: Red Cell Transfusion Goals in Patients With Acute Leukemias (clinicaltrials.gov) - May 13, 2016
P0, N=90, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Aug 2016
- dilanubicel (DVX101) / Deverra Therapeutics
Trial primary completion date: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 1, 2016
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Aug 2016 Trial primary completion date: May 2016 --> Dec 2016
- || vadastuximab talirine (SGN-CD33A) / Pfizer
Enrollment status: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Mar 25, 2016
P1, N=225, Enrolling by invitation, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: May 2016 --> Dec 2016 Recruiting --> Enrolling by invitation
- arsenic trioxide / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial termination, IO biomarker: Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Dec 18, 2015
P2, N=1, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Enrolling by invitation Completed --> Terminated; Lack of accrual
- || vadastuximab talirine (SGN-CD33A) / Pfizer
Trial primary completion date: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Dec 9, 2015
P1, N=225, Recruiting, Sponsor: Seattle Genetics, Inc.
Completed --> Terminated; Lack of accrual Trial primary completion date: Jan 2016 --> Jun 2017
- arsenic trioxide / Generic mfg.
Trial primary completion date: New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov) - Oct 27, 2015
P2, N=0, Withdrawn, Sponsor: University of Southern California
Trial primary completion date: Jan 2016 --> Jun 2017 Trial primary completion date: May 2011 --> Aug 2010
- cytarabine / Generic mfg., clofarabine / Generic mfg., sorafenib / Generic mfg.
Trial completion, Enrollment change, Combination therapy: Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Jul 13, 2015
P1, N=44, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: May 2011 --> Aug 2010 Recruiting --> Completed | N=60 --> 44
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2015
P2, N=6, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed | N=60 --> 44 Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011
- Trial primary completion date: Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database (clinicaltrials.gov) - Jul 2, 2015
P=N/A, N=120, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011 Trial primary completion date: Jun 2016 --> Nov 2017
- Biomarker, Trial completion: Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - May 7, 2015
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Jun 2016 --> Nov 2017 Active, not recruiting --> Completed
- | cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion, Enrollment change, Combination therapy: Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - May 7, 2015
P1/2, N=50, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=19 --> 50
- | arsenic trioxide / Generic mfg.
Trial completion: Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=19 --> 50 No longer recruiting --> Completed
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial completion, Enrollment change, Trial primary completion date: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=2, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
No longer recruiting --> Completed Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015
- cytarabine / Generic mfg., clofarabine / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Combination therapy: Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Jan 13, 2015
P1, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015 Trial primary completion date: Jan 2015 --> Jun 2015
- lenalidomide / Generic mfg., cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion: Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 24, 2014
P1, N=61, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2015 --> Jun 2015 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Trial completion: Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Dec 24, 2014
P1, N=17, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Beleodaq (belinostat) / Aurobindo, Assertio
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (clinicaltrials.gov) - Dec 24, 2014
P1, N=56, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=33 --> 56 | Trial primary completion date: Aug 2011 --> Mar 2013
- Clinical: Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=120, Recruiting, Sponsor: Emory University
- busulfan / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment change, Trial termination: ASCT for Relapsed APL After Molecular Remission (clinicaltrials.gov) - Dec 5, 2014
P2, N=5, Terminated, Sponsor: Shanghai Jiao Tong University School of Medicine
Active, not recruiting --> Completed | N=33 --> 56 | Trial primary completion date: Aug 2011 --> Mar 2013 N=30 --> 5 | Recruiting --> Terminated; slow recruitment